Joshua Augustine, MD
Nephrology · Cleveland, OHNPI 1053330456
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Novo Nordisk at 50.1% of the total. 2025 is the largest year on record at $2,366, more than ten times the $206 reported in 2019.
Across 13 payments — averaging $333.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- One Lambda, Inc.$900
- Sanofi-aventis U.S. LLC$450
- Otsuka America Pharmaceutical, Inc.$341
- Novartis$164
- Travere Therapeutics, Inc.$143
- plus $165 from 3 others
What the payments were for
- Consulting fees$2,17050%
- Speaking & faculty fees$1,35031%
- Food & beverage$81419%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 2 | $2,170 |
| One Lambda, Inc. | 1 | $900 |
| Sanofi-aventis U.S. LLC | 1 | $450 |
| Otsuka America Pharmaceutical, Inc. | 3 | $341 |
| Novartis | 2 | $164 |
| Travere Therapeutics, Inc. | 1 | $143 |
| E.r. Squibb & Sons, L.L.C. | 1 | $95 |
| Gilead | 1 | $40 |
| AstraZeneca | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rivfloza$2,170
- THYMOGLOBULIN$450
- LEMTRADA$450
- JYNARQUE$341
- ZORTRESS$111
How this compares
$4,334 in reported general payments places this provider in the 80th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $10,839 |
| Valganciclovir Hcl | 51 | $10,184 |
| Tacrolimus | 40 | $8,587 |
| Cinacalcet Hcl | 26 | $7,788 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 380 | $3,685 |
| Mycophenolate Mofetil | 36 | $3,400 |
| Prednisone | 378 | $2,397 |
| Nifedipine ErNifedipine | 73 | $2,046 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $1,108 |
| Amlodipine Besylate | 162 | $1,104 |
| Pantoprazole Sodium | 64 | $982 |
| Carvedilol | 169 | $938 |
| Methenamine Hippurate | 19 | $916 |
| Propranolol Hcl ErPropranolol Hcl | 20 | $815 |
| Spironolactone-HctzSpironolact/Hydrochlorothiazid | 24 | $802 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Cleveland
- Georges NakhoulCleveland$255K
- Sankar NavaneethanCleveland$253K
- Sevag DemirjianCleveland$158K
- Elias BassilCleveland$80K
- Ali MehdiCleveland$76K
- Amitkumar PatelCleveland$70K
- Emilio PoggioCleveland$41K
- Corey CavanaughCleveland$35K
- James SimonCleveland$29K
- Ziad ZakyCleveland$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.